Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment

• Үндсэн зохиолчид: Luis Sarabia De Ardanaz (Зохиогч), Jose M. Andreu-Ubero (Зохиогч), Miriam Navidad-Fuentes (Зохиогч), Miguel Ángel Ferrer-González (Зохиогч), Victor Ruíz del Valle (Зохиогч), Inmaculada Salcedo-Bellido (Зохиогч), Rocío Barrios-Rodríguez (Зохиогч), Rafael Cáliz-Cáliz (Зохиогч), Pilar Requena (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In additi...